MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2023 International Congress

    Feasibility, Reliability and Value of Remote Levodopa Challenge Test in Parkinson’s Disease

    Z. Zeng, W. Shi, X. Wan, Z. Lin, Z. Chen, C. Zhang (Shanghai, China)

    Objective: To demonstrate the feasibility, reliability, and value of the remote L-dopa challenge test (LCT) in candidate screening for deep brain stimulation (DBS) in patients…
  • 2023 International Congress

    Exercise and levodopa metabolism in Parkinson disease

    M. Figura, J. Giebułtowicz, A. Mrozowicz, S. Szlufik, D. Koziorowski (Warsaw, Poland)

    Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…
  • 2023 International Congress

    NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)

    P. Svenningsson, P. Odin, F. Berquist, K. Wirdefeldt, D. Nyholm, M. Andréasson, I. Markaki, A. Johansson, M. Jergil, C. Jankosky, M. Varney, F. Herbrecht, S. Johnson, A. Newman-Tancredi (Solna, Sweden)

    Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…
  • 2023 International Congress

    What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)

    R. Hauser, S. Allard, G. Banisadr, S. Fisher (Tampa, USA)

    Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…
  • 2023 International Congress

    The diagnosis value of dopaminergic responsiveness of Parkinson’s disease: a systematic review and meta-analysis

    WY. Kou, HH. Cai, FT. Feng (beijiing, China)

    Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…
  • 2023 International Congress

    Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.

    P. Odin, T. Kimber, B. Bergmans, E. Freire-Alvarez, F. Gandor, S. Isaacson, S. Dhanani, R. Hauser, M. O'Meara, A. Jeong, J. Jia, R. Gupta, L. Bergmann, M. Shah, L. Harmer, S. Talapala, J. Aldred (Lund, Sweden)

    Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
  • 2023 International Congress

    Effect of levodopa on the interpretation of social interactions in people living with Parkinson’s disease

    T. Danaila, E. Metereau (Bron, France)

    Objective: Better understand the social interactions by assessing the effect of oral levodopa on the social cognition abilities in fluctuating PD patients without significant cognitive disorder.…
  • 2023 International Congress

    Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study

    B. Biering-Sørensen, N. Nielsen, A. Isenberg, L. Olsen, M. Javidi, J. Vilhelmsen, M. Møller, M. Olsen, J. Clausen, T. Thomsen (Glostrup, Denmark)

    Objective: Primary objectives were to assess the feasibility and safety of LCIG home titration with use of telemedicine-assisted (TM) technology, and  patient/caregivers satisfaction. Secondly, to…
  • 2023 International Congress

    Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult

    J. Nataraj, J. Maclean, SA. Seyyed Mousavi, J. Olaya, M. Liker, T. Sanger (Irvine, USA)

    Objective: To evaluate effects of acute levodopa administration on frequency content of intracranial local field potentials in a dystonic young adult. Background: Levodopa is the…
  • 2023 International Congress

    Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study

    J. Aldred, R. Rodriguez, E. Rivera-Rivera, S. Isaacson, R. Kumar, A. Ellenbogen, C. Ahlem, C. Reading, J. Palumbo, N. Osman, A. Lang (Spokane, USA)

    Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley